Showing 2551-2560 of 4902 results for "".
Ethics and Dermatology: Finding Harmony in Daily Practice
https://practicaldermatology.com/topics/general-topics/PD0109_06-php/22893/While there are no easy resolutions to ethical dilemmas, experts emphasize the importance of reflection and discussion in building higher ethical standards.Acne Treatment Advances
https://practicaldermatology.com/topics/acne-rosacea/acne-treatment-advances/23506/Boosting adherence and results with energy-based devices.Hyperpigmentation Treatment Pearls and More
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/hyperpigmentation-treatment-pearls-and-more/20161/Corey Hartman, MD shares his approach to treating periorbital hyperpigmentation in darker skin types, including using fillers to replace volume, give lift, and replace loss of bony structures and fat pads. Dr. Hartman also discusses the benefits of Cynosure’s PicoSure device to correct hyperpigmentaDermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global PUpdates on AD Therapeutics
https://practicaldermatology.com/topics/atopic-dermatitis/updates-on-ad-therapeutics/19760/It's a "super-exciting" time in the world of atopic dermatitis because of a number of new developments happening very rapidly, shares Peter Lio, MD. Recent approvals and additional indications for treatments like dupilumab and crisaborole in pediatric populations have been welcome additions. And theIdentifying SCC Risk
https://practicaldermatology.com/topics/skin-cancer-photoprotection/identifying-scc-risk/20144/Sherrif Ibrahim, MD discusses the challenges of managing squamous cell carcinoma (SCC). Great steps have been made in clinical, pathological staging systems, but Dr. Ibrahim says it’s still difficult to determine what to do with borderline cases. He talks about the need to determine frequency and inNew Treatment Algorithms for Actinic Keratoses
https://practicaldermatology.com/topics/skin-cancer-photoprotection/new-treatment-algorithms-for-actinic-keratoses/18812/Gary Goldenberg, MD reviews the literature showing why all actinic keratoses (AKs) need to be treated and why it's important to treat the field and not just the visible lesions. He shares his evidence-based, time-sequential therapy approach to combining a destructive modality with field therapy to pTeledermatology Update
https://practicaldermatology.com/topics/practice-management/teledermatology-update/20146/Many dermatologists and dermatologic surgeons adopted teledermatology or began to use it more frequently throughout the COVID pandemic. Many consultations and post-operative follow-up appointments were handled through telemedicine platforms. Anthony Rossi, MD talks about the benefits of this technolManaging Comorbidites of Psoriasis
https://practicaldermatology.com/topics/psoriasis/managing-comorbidites-of-psoriasis/18808/Ron Prussick, MD explains why it's important for dermatologists to discuss the risks of comorbidities such as cardiovascular events, fatty liver disease, depression, and more with patients with psoriasis. While it needs to be determined if the treatments used to treat the outside effects of psoriasiDefending Sunscreens
https://practicaldermatology.com/topics/skin-cancer-photoprotection/defending-sunscreens/19980/Sunscreen controversies have been a hot topic leaving patients with many questions about its safety and proper use. Adam Friedman, MD offers tips for talking to patients about what is really needed in an SPF, applying the right amount of sunscreen for adequate protection, and discussing data to help